Literature DB >> 18324890

Current challenges in the development of vaccines for pneumonic plague.

Stephen T Smiley1.   

Abstract

Inhalation of Yersinia pestis bacilli causes pneumonic plague, a rapidly progressing and exceptionally virulent disease. Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic plague vaccine. These facts raise concern that Y. pestis may be exploited as a bioweapon. Here, I review the history and status of plague vaccine research and advocate that pneumonic plague vaccines should strive to prime both humoral and cellular immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324890      PMCID: PMC2365752          DOI: 10.1586/14760584.7.2.209

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  118 in total

1.  Construction of defined F1 negative mutants of virulent Yersinia pestis.

Authors:  P L Worsham; M P Stein; S L Welkos
Journal:  Contrib Microbiol Immunol       Date:  1995

2.  Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits.

Authors:  J E Eyles; E D Williamson; I D Spiers; A J Stagg; S M Jones; H O Alpar
Journal:  J Control Release       Date:  2000-01-03       Impact factor: 9.776

Review 3.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

4.  Plague immunization. V. Indirect evidence for the efficacy of plague vaccine.

Authors:  D C Cavanaugh; B L Elisberg; C H Llewellyn; J D Marshall; J H Rust; J E Williams; K F Meyer
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

5.  Plague bacillus: survival within host phagocytes.

Authors:  W A Janssen; M J Surgalla
Journal:  Science       Date:  1969-02-28       Impact factor: 47.728

6.  Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs.

Authors:  K F Meyer; G Smith; L Foster; M Brookman; M Sung
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

7.  Pneumonic plague in an untreated plague-vaccinated individual.

Authors:  R J Cohen; J L Stockard
Journal:  JAMA       Date:  1967-10-23       Impact factor: 56.272

8.  Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis.

Authors:  Kimberly Pouliot; Ning Pan; Shixia Wang; Shan Lu; Egil Lien; Jon D Goguen
Journal:  Infect Immun       Date:  2007-04-16       Impact factor: 3.441

9.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates.

Authors:  Yehuda Flashner; Emanuelle Mamroud; Avital Tidhar; Raphael Ber; Moshe Aftalion; David Gur; Shirley Lazar; Anat Zvi; Tamar Bino; Naomi Ariel; Baruch Velan; Avigdor Shafferman; Sara Cohen
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more
  83 in total

1.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

2.  Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation.

Authors:  R Colby Layton; Trevor Brasel; Andrew Gigliotti; Edward Barr; Steven Storch; Leslie Myers; Charles Hobbs; Frederick Koster
Journal:  J Med Primatol       Date:  2010-08-16       Impact factor: 0.667

3.  Deletion of Braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague.

Authors:  Christina J van Lier; Jian Sha; Michelle L Kirtley; Anthony Cao; Bethany L Tiner; Tatiana E Erova; Yingzi Cong; Elena V Kozlova; Vsevolod L Popov; Wallace B Baze; Ashok K Chopra
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

4.  A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.

Authors:  Yue Zhang; Patricio Mena; Galina Romanov; Jr-Shiuan Lin; Stephen T Smiley; James B Bliska
Journal:  Infect Immun       Date:  2011-11-07       Impact factor: 3.441

5.  Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague.

Authors:  Stephen T Smiley; Frank M Szaba; Lawrence W Kummer; Debra K Duso; Jr-Shiuan Lin
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

6.  Yersinia pestis IS1541 transposition provides for escape from plague immunity.

Authors:  Claire A Cornelius; Lauriane E Quenee; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 7.  Plague gives surprises in the first decade of the 21st century in the United States and worldwide.

Authors:  Thomas Butler
Journal:  Am J Trop Med Hyg       Date:  2013-09-16       Impact factor: 2.345

8.  Amino acid residues 196-225 of LcrV represent a plague protective epitope.

Authors:  Lauriane E Quenee; Bryan J Berube; Joshua Segal; Derek Elli; Nancy A Ciletti; Deborah Anderson; Olaf Schneewind
Journal:  Vaccine       Date:  2009-12-10       Impact factor: 3.641

9.  Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague.

Authors:  Wei Sun; Kenneth L Roland; Xiaoying Kuang; Christine G Branger; Roy Curtiss
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

10.  In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine.

Authors:  Pan Tao; Marthandan Mahalingam; Bernard S Marasa; Zhihong Zhang; Ashok K Chopra; Venigalla B Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.